Case Report
Use of the CellSearch™ Circulating Tumor Cell Test for Monitoring Urothelial Cancer: Two Case Reports of Metastatic Urothelial Cancer
Abstract
Until now, there have been no reliable serum markers for monitoring urothelial cancers. However, it has been reported that it is possible to detect circulating urothelial cancer cells using the CellSearch™ Circulating Tumor Cell (CCTC™) Test (Immunicon, Huntingdon Valley, PA). (1) This case report is a representative example of the good correlation between the change of the number of circulating tumor cells in the blood and the state of an urothelial cancer after therapies. Detection of circulating tumor cells might be a valuable serum marker for urothelial cancer patients with distant metastasis.
Key Points
* There have been no reliable serum markers for monitoring urothelial cancers.
* It is possible to detect circulating urothelial cancer cells with the CCTC™ Test (Immunicon, Huntingdon Valley, PA).
* Knowing the number of circulating tumor cells may assist oncologists in making critical decisions about patients’ treatment earlier than previously possible.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.